NASDAQ:NKTX Nkarta (NKTX) Stock Price, News & Analysis $2.12 -0.08 (-3.64%) Closing price 04:00 PM EasternExtended Trading$2.12 +0.00 (+0.24%) As of 04:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Nkarta Stock (NASDAQ:NKTX) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Nkarta alerts:Sign Up Key Stats Today's Range$2.08▼$2.2050-Day Range$1.66▼$2.3752-Week Range$1.31▼$6.63Volume345,977 shsAverage Volume928,993 shsMarket Capitalization$150.57 millionP/E RatioN/ADividend YieldN/APrice Target$13.60Consensus RatingBuy Company Overview Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. The company's lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen that is in Phase 1 clinical trial for the treatment of relapsed/refractory (r/r) non-hodgkin lymphoma, as well as for lupus nephritis. It also develops NKX101, a CAR NK product candidate targeting cells that display NKG2D ligands, which is in Phase I clinical trial for the treatment of r/r acute myeloid leukemia or higher risk myelodysplastic syndromes, as well as for solid tumors. In addition, the company develops NKX070, targeting the CD70 tumor antigen to treat solid and liquid tumors; and NK+T cell therapy for use in the treatment of oncology, autoimmune disease, or infectious disease. It has a research collaboration agreement with CRISPR Therapeutics AG. Nkarta, Inc. was incorporated in 2015 and is based in South San Francisco, California. Read More Nkarta Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks42nd Percentile Overall ScoreNKTX MarketRank™: Nkarta scored higher than 42% of companies evaluated by MarketBeat, and ranked 680th out of 944 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingNkarta has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageNkarta has only been the subject of 3 research reports in the past 90 days.Read more about Nkarta's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Nkarta are expected to decrease in the coming year, from ($1.70) to ($1.80) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Nkarta is -1.43, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Nkarta is -1.43, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioNkarta has a P/B Ratio of 0.42. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Nkarta's valuation and earnings. Short Interest0.0 / 5Short Interest LevelBearish Percentage of Shares Shorted12.43% of the float of Nkarta has been sold short.Short Interest Ratio / Days to CoverNkarta has a short interest ratio ("days to cover") of 16.5, which indicates bearish sentiment.Change versus previous monthShort interest in Nkarta has recently increased by 6.32%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldNkarta does not currently pay a dividend.Dividend GrowthNkarta does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted12.43% of the float of Nkarta has been sold short.Short Interest Ratio / Days to CoverNkarta has a short interest ratio ("days to cover") of 16.5, which indicates bearish sentiment.Change versus previous monthShort interest in Nkarta has recently increased by 6.32%, indicating that investor sentiment is decreasing significantly. News and Social Media3.5 / 5News Sentiment1.24 News SentimentNkarta has a news sentiment score of 1.24. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 1.03 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Nkarta this week, compared to 2 articles on an average week.Search Interest8 people have searched for NKTX on MarketBeat in the last 30 days. This is an increase of 167% compared to the previous 30 days.MarketBeat Follows2 people have added Nkarta to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Nkarta insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 8.40% of the stock of Nkarta is held by insiders.Percentage Held by Institutions80.54% of the stock of Nkarta is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Nkarta's insider trading history. Receive NKTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Nkarta and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. NKTX Stock News HeadlinesNkarta (NASDAQ:NKTX) Stock Rating Upgraded by Wall Street ZenAugust 19, 2025 | americanbankingnews.comNkarta price target lowered to $12 from $14 at StifelAugust 15, 2025 | msn.comElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… The "experts" said Elon was finished and Tesla was headed for bankruptcy. Now they're saying the same thing, but Jeff has uncovered Tesla's next breakthrough.August 29 at 2:00 AM | Brownstone Research (Ad)Nkarta, Inc.: Nkarta Reports Second Quarter 2025 Financial Results and Corporate HighlightsAugust 13, 2025 | finanznachrichten.deNkarta, Inc. Reports Q2 2025 Financial ResultsAugust 12, 2025 | tipranks.comNkarta Reports Second Quarter 2025 Financial Results and Corporate HighlightsAugust 12, 2025 | globenewswire.comNkarta to Participate in the H.C. Wainwright "HCW@Home" SeriesJuly 23, 2025 | tmcnet.comNkarta to Participate in the H.C. Wainwright “HCW@Home” SeriesJuly 23, 2025 | globenewswire.comSee More Headlines NKTX Stock Analysis - Frequently Asked Questions How have NKTX shares performed this year? Nkarta's stock was trading at $2.49 at the beginning of 2025. Since then, NKTX shares have decreased by 14.9% and is now trading at $2.12. How were Nkarta's earnings last quarter? Nkarta, Inc. (NASDAQ:NKTX) released its quarterly earnings data on Tuesday, August, 12th. The company reported ($0.31) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.37) by $0.06. When did Nkarta IPO? Nkarta (NKTX) raised $150 million in an initial public offering (IPO) on Friday, July 10th 2020. The company issued 10,000,000 shares at a price of $14.00-$16.00 per share. Cowen, Evercore ISI, Stifel and Mizuho Securities acted as the underwriters for the IPO. Who are Nkarta's major shareholders? Top institutional investors of Nkarta include Wasatch Advisors LP (2.51%), Monaco Asset Management SAM (2.23%), Geode Capital Management LLC (1.70%) and Bank of America Corp DE (1.05%). Insiders that own company stock include Simeon George, Paul J Hastings, David Shook, James Trager, Alicia J Hager and Ralph Brandenberger. View institutional ownership trends. How do I buy shares of Nkarta? Shares of NKTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Nkarta own? Based on aggregate information from My MarketBeat watchlists, some other companies that Nkarta investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Broadcom (AVGO), Adobe (ADBE), CrowdStrike (CRWD) and Arista Networks (ANET). Company Calendar Last Earnings8/12/2025Today8/29/2025Next Earnings (Estimated)11/06/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:NKTX CIK1787400 Webwww.nkartatx.com Phone925-407-1049FaxN/AEmployees140Year FoundedN/APrice Target and Rating Average Price Target for Nkarta$13.60 High Price Target$18.00 Low Price Target$10.00 Potential Upside/Downside+518.2%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage7 Analysts Profitability EPS (Trailing Twelve Months)($1.48) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$108.79 million Net MarginsN/A Pretax MarginN/A Return on Equity-27.74% Return on Assets-22.38% Debt Debt-to-Equity RatioN/A Current Ratio15.67 Quick Ratio15.67 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$5.04 per share Price / Book0.44Miscellaneous Outstanding Shares71,025,000Free Float65,059,000Market Cap$156.26 million OptionableOptionable Beta0.72 Social Links Analysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free Report This page (NASDAQ:NKTX) was last updated on 8/29/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredThis is my Christian duty“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Nkarta, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Nkarta With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.